OABI OmniAb, Inc.
Services-Commercial Physical & Biological Research · Nasdaq · SEC CIK 1846253 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY90.6%
TTM net income YoY31.7%
TTM EPS YoY42.4%
Revenue 3-yr CAGR-14.7%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-115.9%
Net margin-108.1%
FCF margin5.9%
EBITDA margin-64.2%
Returns
ROE-16.5%
ROA-14.5%
ROIC (approx.)-15.5%
Asset turnover0.13x
Leverage & solvency
Liabilities / assets14.4%
Debt / equity0.00x
Current ratio4.21x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.06x
Accruals ratio-15.4%
Payout ratio—
Capex / revenue0.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $18.67M | $26.39M |
| R&D expense | $47.75M | $55.11M |
| SG&A expense | $29.21M | $30.74M |
| Operating income | -$68.97M | -$74.50M |
| Pretax income | -$66.29M | -$71.41M |
| Income tax | -$1.51M | -$9.38M |
| Net income | -$64.78M | -$62.03M |
| EBITDA | -$47.22M | -$50.92M |
| EPS (basic) | -0.57 | -0.61 |
| EPS (diluted) | -0.57 | -0.61 |
| Weighted avg. shares (diluted) | 113.64M | 102.36M |
| Balance sheet | ||
| Cash & equivalents | $25.52M | $28.16M |
| Short-term investments | $28.50M | $31.84M |
| Receivables | $7.39M | $5.27M |
| Inventory | $823,000 | $48,000 |
| Current assets | $65.34M | $68.14M |
| PP&E, net | $9.43M | $15.49M |
| Goodwill | $83.98M | $83.98M |
| Intangibles | $125.15M | $138.06M |
| Total assets | $300.91M | $325.56M |
| Current liabilities | $16.25M | $15.09M |
| Total liabilities | $33.89M | $37.94M |
| Shareholders' equity | $267.03M | $287.62M |
| Shares outstanding | 144.31M | 121.60M |
| Cash flow statement | ||
| Operating cash flow | -$36.45M | -$39.66M |
| Capital expenditure | $565,000 | $1.88M |
| Free cash flow | -$37.02M | -$41.54M |
| Investing cash flow | $6.47M | $37.88M |
| Financing cash flow | $27.91M | $13.02M |
| Depreciation & amortization | $21.75M | $23.58M |
| Stock-based compensation | $15.82M | $21.50M |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.